Transgene S.A.
TNG.PA · PAR
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | €6,353 | €7,900 | €3,126 | €9,993 |
| % Growth | -19.6% | 152.7% | -68.7% | – |
| Cost of Goods Sold | €34,278 | €29,588 | €32,168 | €32,883 |
| Gross Profit | -€27,925 | -€21,688 | -€29,042 | -€22,890 |
| % Margin | -439.6% | -274.5% | -929% | -229.1% |
| R&D Expenses | €34,278 | €29,588 | €32,168 | €32,883 |
| G&A Expenses | €4 | €6,987 | €3,221 | €2,594 |
| SG&A Expenses | €4 | €3,818 | €3,221 | €2,594 |
| Sales & Mktg Exp. | €0 | -€3,169 | €0 | €0 |
| Other Operating Expenses | -€26,549 | -€25,047 | -€2,136 | -€1,738 |
| Operating Expenses | €7,733 | €8,359 | €33,253 | €33,739 |
| Operating Income | -€35,658 | -€30,047 | -€29,904 | -€23,525 |
| % Margin | -561.3% | -380.3% | -956.6% | -235.4% |
| Other Income/Exp. Net | €1,687 | €7,719 | -€2,900 | €4,159 |
| Pre-Tax Income | -€40,017 | -€22,328 | -€32,804 | -€19,536 |
| Tax Expense | €0 | €0 | €6 | €468 |
| Net Income | -€33,971 | -€22,328 | -€32,810 | -€20,004 |
| % Margin | -534.7% | -282.6% | -1,049.6% | -200.2% |
| EPS | -0.29 | -0.22 | -0.33 | -0.22 |
| % Growth | -31.8% | 33.3% | -50% | – |
| EPS Diluted | -0.29 | -0.22 | -0.33 | -0.22 |
| Weighted Avg Shares Out | 116,667 | 101,491 | 99,502 | 91,112 |
| Weighted Avg Shares Out Dil | 116,667 | 100,590 | 99,502 | 91,112 |
| Supplemental Information | – | – | – | – |
| Interest Income | €1,362 | €7,338 | €309 | €4,198 |
| Interest Expense | €1,681 | €0 | €804 | €464 |
| Depreciation & Amortization | €1,353 | €1,572 | €1,673 | €2,509 |
| EBITDA | -€26,652 | -€28,440 | -€30,327 | -€23,550 |
| % Margin | -419.5% | -360% | -970.2% | -235.7% |